Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

NCT07431307 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Ventilator Associated Bacterial Pneumonia (VABP)
Hospital Acquired Bacterial Pneumonia (HABP)
Blood Stream Infection
Meningitis, Bacterial
Ventriculitis, Infectious

Interventions

DRUG: BV100 with 50 mg polymyxin B plus ceftazidime/avibactam
DRUG: BV100 with 50 mg polymyxin B plus cefiderocol
DRUG: Best Available Therapy (BAT)

Sponsor

BioVersys AG